Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tPA in Suprachoroidal and Subretinal Hemorrhage
NCT05736757Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of tissue-plasminogen activator in Suprachoroidal Hemorrhage (SCH) and Subretinal Hemorrhage (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Best Corrected Visual Acuity at 2 years. Started Dec 2022; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
Suprachoroidal Hemorrhage (SCH)Subretinal Hemorrhage
Beyond the preview
Go deeper on NCT05736757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736757.